ARTICLE | Clinical News
Alacrity's ALTY-0501 misses dry eye endpoint
October 10, 2007 1:13 AM UTC
Alacrity (Laguna Hills, Calif.) said ALTY-0501 missed the primary endpoint of a significant reduction in central corneal damage compared with placebo following exposure to a controlled adverse environ...